Muscarinic receptor antagonists in the treatment of overactive bladder

Urology

Volumn 55, Issue 5 SUPPL., 2000, Pages 33-46

  Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE; MUSCARINIC RECEPTOR; BENZHYDRYL DERIVATIVE; BENZOFURAN DERIVATIVE; CRESOL; MANDELIC ACID DERIVATIVE; PHENYLPROPANOLAMINE; PYRROLIDINE DERIVATIVE;

CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DRUG EFFICACY; HUMAN; META ANALYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; VISUAL IMPAIRMENT; XEROSTOMIA; BLADDER INSTABILITY; DROWSINESS; DRUG TOLERABILITY; GUINEA PIG; HYPERREFLEXIA; NONHUMAN; SUSTAINED RELEASE FORMULATION; URINE INCONTINENCE; BLADDER DISEASE;

BENZHYDRYL COMPOUNDS; BENZOFURANS; CLINICAL TRIALS; CRESOLS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PYRROLIDINES; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 0033627043     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00492-6     Document Type: Article

References (119)

1. Lenderking W.R., Nackley J.F., Anderson R.B., et al. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 9:1996;11-23.
2. Kobelt G., Kirchberger I., Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine (review). Br J Urol. 83:1999;583-590.
3. Fantl JA, Newman DK, Colling J, et al: Managing Acute and Chronic Urinary Incontinence. Clinical Practice Guidelines. Quick Reference Guide for Clinicians, No. 2, 1996 Update. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Pub. No. 96-0686, 1996.
4. Abrams P, Khoury S, Wein A (eds): First International Consultation on Incontinence. Plymouth, UK: Health Publications, Ltd, 1999.
5. Yarker Y., Goa K.L., Fitton A. Oxybutynin a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability . Drugs Aging. 6:1995;243-262.
6. Kelleher C.J., Cardozo L.D., Khullar V., et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 104:1997;988-993.
7. Brading A.F. A myogenic basis for the overactive bladder. Urology. 50:(Suppl 6A):1997;57-67.
8. de Groat W.C. A neurologic basis for the overactive bladder. Urology. 50:(Suppl 6A):1997;36-52.
9. Andersson K.-E. The pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 45:1993;253-308.
10. Caulfield M.P., Birdsall N.J.M. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors . Pharmacol Rev. 50:1998;279-290.
11. Wang P., Luthin G.R., Ruggieri M.R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 273:1995;959-966.
12. Hegde S.S., Eglen R.M. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 64:1999;419-428.
13. 3-receptors coupled to inositol phospholipid hydrolysis in human detrusor smooth muscle cells. J Urol. 154:1995;1241-1245.
14. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol. 120:1997;1409-1418.
15. Gillberg P.-G., Sundquist S., Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 349:1998;285-292.
16. Somogyi G.T., de Groat W.C. Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Syst. 37:1992;89-98.
17. Flood HD, Somogyi GT, Bellinger MF, et al: Muscarinic facilitation of acetylcholine release in the human bladder: a mechanism for enhancement of micturition contractions (abst). 24th Annual Meeting of the International Continence Society, Prague, 31 Aug-2 Sept, 1994.
18. Somogyi G.T., Tanowitz M., de Groat W.C. M1 muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder. J Physiol. 480:1994;81-89.
19. 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 4:1995;458-468.
20. 3H]acetylcholine in the rabbit urinary bladder. Eur J Pharmacol. 281:1995;1-8.
21. 3H]acetylcholine release in the rat isolated urinary bladder. J Pharmacol Exp Ther. 283:1997;750-756.
22. Somogyi G.T., de Groat W.C. Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. 64:1999;411-419.
23. Rossman M.E., Merlis S. A clinical evaluation of oxybutynin chloride in the treatment of gastro-intestinal disease. Curr Ther Res. 6:1964;284-289.
24. Hock C.W. Clinical evaluation of oxybutynin chloride. Curr Ther Res. 9:1967;437-440.
25. Diokno A.C., Lapides J. Oxybutynin a new drug with analgesic and anticholinergic properties . J Urol. 108:1972;307-309.
26. Nilvebrant L. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. Acta Pharmacol Toxicol. 59:(Suppl I):1986;1-45.
27. Nilvebrant L., Sparf B. Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol. 123:1986;133-143.
28. Noronha-Blob L., Kachur J.F. Enantiomers of oxybutynin in vitro pharmacological characterization at M1, M2 and M3 receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs . J Pharmacol Exp Ther. 256:1991;562-567.
29. Nilvebrant L., Andersson K.-E., Gillberg P.-G., et al. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 327:1997;195-207.
30. Batra S., Björklund A., Hedlund H., et al. Identification and characterization of muscarinic cholinergic receptors in the human urinary bladder and parotid gland. J Auton Nerv Syst. 20:1987;129-135.
31. Waldeck K., Larsson B., Andersson K.-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol. 157:1997;1093-1097.
32. Tonini M., Rizzi C.A., Perucca E., et al. Depressant action of oxybutynin on the contractility or intestinal and urinary tract smooth muscle. J Pharm Pharmacol. 39:1987;103-107.
33. Kachur J.F., Peterson J.S., Carter J.P., et al. R and S enantiomers of oxybutynin pharmacological effects in guinea pig bladder and intestine . J Pharmacol Exp Ther. 247:1988;867-872.
34. Peterson J.S., Patton A.J., Noronha-Blob L. Mini-pig urinary bladder function comparisons of in vitro anticholinergic responses and in vivo cystometry with drugs indicated for urinary incontinence . J Auton Pharmacol. 10:1990;65-73.
35. Yono M., Yoshida M., Wada Y., et al. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol. 368:1999;223-230.
36. Nagy F., Hamvas A., Frang D. Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride). Int Urol Nephrol. 22:1990;519-524.
37. Fredericks C.M., Anderson G.F., Kreulen D.L. A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan) on rabbit detrusor. Invest Urol. 12:1975;317-319.
38. Anderson G.F., Fredericks C.M. Characterization of the oxybutynin antagonism of drug-induced spasms in detrusor. Pharmacology. 15:1977;31-39.
39. Fredericks C.M., Green R.L., Anderson G.F. Comparative in vitro effects of imipramine, oxybutynin, and flavoxate on rabbit detrusor. Urology. 12:1978;487-491.
40. Smith ER, Wright SE, Aberg G, et al: Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline [in German]. Arzneimittelforschung 48: 1012-1018, 1998.
41. Lish P.M., Labudde J.A., Peters E.L., et al. Oxybutynin a musculotropic antispasmodic drug with moderate anticholinergic action . Arch Int Pharmacodyn Ther. 156:1965;467-489.
42. Hughes K.M., Lang J.C.T., Lazare R., et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 22:1992;859-869.
43. Riva D., Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability results from double-blind treatment . Clin Exp Obstet Gynecol. 11:1984;37-42.
44. Zorzitto M.L., Holliday P.J., Jewett M.A., et al. Oxybutynin chloride for geriatric urinary dysfunction a double-blind placebo-controlled study . Age Ageing. 18:1989;195-200.
45. Moore K.H., Hay D.M., Imrie A.E., et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 66:1990;479-485.
46. Tapp A.J.S., Cardozo L.D., Versi E., et al. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride a double blind placebo controlled study . Br J Obstet Gynaecol. 97:1990;521-526.
47. Thüroff J.W., Bunke B., Ebner A., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity oxybutynin versus propantheline versus placebo . J Urol. 145:1991;813-817.
48. Collas D.M., Szonyi G., Ding Y.Y., et al. Oxybutynin with bladder retraining for detrusor instability in the elderly - a placebo controlled trial (abst). Age Ageing. 23:(Suppl 2):1994;9.
49. Ouslander J, Schnelle J, Uman G, et al: Does oxybutynin enhance the effectiveness of prompted voiding for incontinence among nursing home residents? (abst). J Am Geriatr Soc 42: SA1, 1994.
50. Madersbacher H, Halaska M, Voigt R, et al: Tolerability and efficacy of propiverine in patients with urge incontinence in comparison with oxybutynin and placebo (abst). 1st International Consultation on Incontinence, Monaco, 28 Jun-1 Jul, 1998.
51. Gajewski J.B., Awad S.A. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol. 135:1986;966-968.
52. Holmes D.M., Montz F.J., Stanton S.L. Oxybutynin versus propantheline in the management of detrusor instability A patient-regulated variable dose trial . Br J Obstet Gynaecol. 96:1989;607-612.
53. Clarke B. Anticholinergic medication for the unstable bladder prospective trials of imipramine/propantheline versus penthienate and oxybutynin versus penthienate . Int Urogynecol J. 7:1996;191-195.
54. Madersbacher H., Stöhrer M., Richter R., et al. Trospium chloride versus oxybutynin a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia . Br J Urol. 75:1995;452-456.
55. Osca J.M., Martínez-Agullo E., Broseta E., et al. Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders a double blind randomized clinical trial (abst) . Br J Urol. 80:(Suppl 2):1997;12.
56. Brendler B.C.H., Radebaugh L.C., Mohler J.L. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol. 141:1989;1350-1352.
57. Greenfield S.P., Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol. 146:1991;532-534.
58. Madersbacher H., Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia. 29:1991;84-90.
59. Massad C.A., Kogan B.A., Trigo-Rocha F.E. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol. 148:1992;595-597.
60. O'Flynn K.J., Thomas D.G. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. Br J Urol. 72:1993;566-570.
61. Krishnan K.R., Fowler C., Powell J., et al. A double-blind, randomized, placebo controlled, parallel group, multicentre study of intravesical oxybutynin (abst). Neurourol Urodyn. 15:1996;307-308. [Published erratum appears in Neurourol Urodyn 15: 674-676, 1996].
62. Szollar S.M., Lee S.M. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord. 34:1996;284-287.
63. Buyse G., Waldeck K., Verporten C., et al. Intravesical oxybutynin for neurogenic bladder dysfunction less systemic side effects due to reduced first pass metabolism . J Urol. 160:1998;892-896.
64. Fröhlich G, Burmeister S, Wiedemann A, et al: Intravesical trospium chloride, oxybutynin and verapamil for relaxation of detrusor muscle: a placebo-controlled, randomised clinical trial [in German]. Arzneimittelforschung 48: 486-489, 1998.
65. Madersbacher H., Knoll M. Intravesical application of oxybutynin mode of action in controlling detrusor hyperreflexia. Preliminary results . Eur Urol. 28:1995;340-344.
66. Collas D, and Malone-Lee JG. The pharmacokinetic properties of rectal oxybutynin - a possible alternative to intravesical administration (abst). Neurourol Urodyn 16: 346-347, 1997.
67. Winkler H.A., Sand P.K. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J. 9:1998;100-102.
68. Gupta S.K., Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 39:1999;289-296.
69. th Annual Meeting of the American College of Obstetricians and Gynecologists, Philadelphia, 15-19 May 1999.
70. Ditropan® XL Product Information [online]. Dec 1998. Available from URL: http://www.ditropanxl.com/pros/pi.htm.
71. Anderson R.U., Mobley D., Blank B., et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol. 161:1999;1809-1812.
72. Schmidt RA, for the Oxybutynin XL Study Group: Efficacy of controlled-release, once-a-day oxybutynin chloride for urge urinary incontinence (abst). 28th Annual Meeting of the International Continence Society, Jerusalem, 14-17 Sept, 1998.
73. Susset JG, Gleason DM, White CF, et al: Open-label safety and dose conversion/determination of once-daily OROS® oxybutynin chloride for urge urinary incontinence (U-UI) (abst). J Urol 159(No. 5, Suppl): 36, 1998.
74. th Annual Meeting of the American College of Obstetricians and Gynecologists, Philadelphia, 15-19 May 1999.
75. Birns J., Malone-Lee J.G. Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment (abst). Neurourol Urodyn. 16:1997;429-430.
76. Nilsson C.G., Lukkari E., Haarala M., et al. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn. 16:1997;533-542.
77. Ditropan® XL (oxybutynin chloride) Tablets. New Drug Application Approval Letter and Medical Review [online]. NDA 20-897; 6 Dec 1998. Available from URL: http://www.fda.gov/cder/foi/nda/98/20897-appltr-medr.pdf.
78. Anonymous: Ditropan XL needs longer trials to support superiority claim for dry mouth. Pharmaceutical Approvals Monthly 4: 26-27, 1999.
79. Hooper P., Tincello D.G., Richmond D.H. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability a pilot study . Br J Urol. 80:1997;414-416.
80. McCullough JR, Aberg G, Wright SE, et al: The antimuscarinic and antispasmodic actions of oxybutynin, its metabolite desethyloxybutynin and their enantiomers (abst). 26th Annual Meeting of the International Continence Society, Athens, 27-30 Aug, 1996.
81. Koch P., McCullough J.R., Blum P.S., et al. Pharmacokinetics and safety of (S)-oxybutynin in normal healthy volunteers (abst). FASEB J. 12:1998;A142.
82. Nilvebrant L., Hallén B., Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist preclinical pharmacological and clinical data . Life Sci. 60:1997;1129-1136.
83. Nilvebrant L., Gillberg P.-G., Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol. 81:1997;169-172.
84. Naerger H., Fry C.H., Nilbebrant L. Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders (abst). Neurourol Urodyn. 14:(part 5):1995;524-526.
85. Eglen R.M., Reddy H., Watson N., et al. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci. 15:1994;114-119.
86. Eglen R.M., Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 78:1996;59-68.
87. Stahl M., Ekström B., Sparf B., et al. Urodynamic and other effects of tolterodine a novel antimuscarinic drug for the treatment of detrusor overactivity . Neurourol Urodyn. 14:1995;647-655.
88. Brynne N., Stahl M.M.S., Hallén B., et al. Pharmacokinetics and pharmacodynamics of tolterodine in man a new drug for the treatment of urinary bladder overactivity . Int J Clin Pharmacol Ther. 35:1997;287-295.
89. Hills C.J., Winter S.A., Balfour J.A. Tolterodine. Drugs. 55:1998;813-820.
90. Abrams P, Jackson S, Mattiasson A, et al: A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia (abst). 26th Annual Meeting of the International Continence Society, Athens, 27-30 Aug, 1996.
91. Rentzhog L., Stanton S.L., Cardozo L., et al. Efficacy and safety of tolterodine in patients with detrusor instability a dose-ranging study . Br J Urol. 81:1998;42-48.
92. Van Kerrebroeck P.E.V.A., Amarenco G., Thüroff J.W., et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn. 17:1998;499-512.
93. Larsson G., Hallén B., Nilvebrant L. Tolterodine in the treatment of overactive bladder analysis of the pooled phase II efficacy and safety data . Urology. 53:1999;990-998.
94. Van Kerrebroeck PEVA, Serment G, and Dreher E: Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder (abst). Neurourol Urodyn 16: 478-479, 1997.
95. Abrams P., Freeman R., Anderström C., et al. Tolterodine, a new antimuscarinic agent as effective but better tolerated than oxybutynin in patients with an overactive bladder . Br J Urol. 81:1998;801-810.
96. Drutz H, Appell RA, Gleason D, et al: Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J (in press).
97. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder a pooled analysis . Urology. 50:(Suppl 6A):1997;90-96.
98. TM Physician Package Insert [online]. Mar 1998. Available from URL: http://www.pnu.com/files/detrol. pdf.
99. Nilvebrant L, Påhlman I, and d'Argy R: Tolterodine and its metabolites show very low penetration into the central nervous system (abst). 29th Annual Meeting of the International Continence Society, Denver, CO, 22-26 Aug, 1999.
100. Malone-Lee JG, Eriksson M, Olofsson S, et al: The comparative tolerability and efficacy of tolterodine 2 mg bid versus oxybutynin 2.5/5 mg bid in the treatment of the overactive bladder (abst). 28th Annual Meeting of the International Continence Society, Jerusalem, 14-17 Sept, 1998.
101. Abrams P, and Larsson G: Long-term tolerability and efficacy of tolterodine in the treatment of the overactive bladder (abst). 28th Annual Meeting of the International Continence Society, Jerusalem, 14-17 Sept, 1998.
102. Drutz H, Abrams P, Appell RA, et al: Long-term treatment of 854 overactive bladder patients with tolterodine (abst). 23rd Annual Meeting of the International Urogynecological Association, Buenos Aires, 18-21 Nov, 1998.
103. Wein A., Abrams P., Drutz H.P., et al. Tolterodine is effective and well tolerated during long-term use in patients with overactive bladder (abst). J Urol. 161:(Suppl):1999;35.
104. Wallis R.M., Napier C.M. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci. 64:1999;395-401.
105. 3 antagonist. Pharmacol Res. 31:(Suppl):1995;54.
106. Nunn P.A., Greengrass P.M., Newgreen D.T., et al. The binding profile of the novel muscarinic receptor antagonist darifenacin against the five cloned human muscarinic receptors expressed in CHO cells. Br J Pharmacol. 117:(Suppl):1996;130P.
107. Eglen R.M., Bonhaus D.W., Calixto J.J., et al. Characterization of the interaction of tolterodine at muscarinic receptor subtypes in vitro and in vivo. Br J Pharmacol. 120:(Suppl):1997;63P.
108. 3 receptors. J Recept Signal Transduct Res. 17:1997;177-184.
109. Chua C.B., Harriss D.R., Marsh K.A., et al. Effect of darifenacin on muscarinic responses in normal and unstable human detrusor smooth muscle cells (abst). Neurourol Urodyn. 16:1997;355-356.
110. Newgreen DT, and Naylor AM. Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutynin (abst). Br J Pharmacol. 117:(Suppl):1996;107P.
111. 3 receptor antagonists. Life Sci. 56:1995;861-868.
112. Newgreen D.T., Anderson C.W.P., Carter A.J., et al. Darifenacin - a novel bladder-selective agent for the treatment of urge incontinence (abst). Neurourol Urodyn. 14:1995;555-557.
113. 3 receptor antagonists on bladder contractions & salivation in anesthetized rats (abst). 26th Annual Meeting of the International Continence Society, Athens, 27-30 Aug, 1996.
114. Williamson I.I.R., Newgreen D.T., Naylor A.M. The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat (abst). Br J Pharmacol. 120:(Suppl):1997;205P.
115. 3 receptor antagonist (abst). Br J Pharmacol. 119:(Suppl):1996;198P.
116. Sawyer P.J.T., McRitchie B., Merner P.A., et al. In vivo gut selectivity of the novel muscarinic antagonist, darifenacin, in the conscious dog (abst). Br J Pharmacol. 118:(Suppl):1996;144P.
117. Choppin A., Eglen R.M., Hegde S.S. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol. 124:1998;883-888.
118. Rosario D.J., Cutinha P.E., Chapple C.R., et al. The effects of single dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability (abst). Eur Urol. 30:(Suppl 2):1996;240.
119. Toozs-Hobson P, Kelleher C, and Cardozo L: A longitudinal study of the effect of darifenacin on the quality of life (abst). 26th Annual Meeting of the International Continence Society, Athens, August 27-30, 1996.